ANDA 213878, held by MSN Laboratories. Cabozantinib S-Malate.
As of Nov 21, 2026, ANDA 213878 (Cabozantinib S-Malate), held by MSN Laboratories, was first approved by FDA on Aug 14, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 2026 | Original application | Approved |
| Cabozantinib S-MalateEQ 20MG BASE · tablet;oral | Cabozantinib S-Malate | Rx |
| Cabozantinib S-MalateEQ 40MG BASE · tablet;oral | Cabozantinib S-Malate | Rx |
| Cabozantinib S-MalateEQ 60MG BASE · tablet;oral | Cabozantinib S-Malate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters